Palladia Canine Osteosarcoma Studies
New studies in canine osteosarcoma (K9 OSA) are underway with cancer drug Palladia. Originally approved by the Food and Drug Administration in 2009, specifically as a cancerous mast cell tumor treatment in dogs, the drug is likely to act primarily through inhibition of the kit tyrosine kinase, though it may also cut off the blood supply to tumor cells to shrink or prevent growth of tumors. Pfizer claims success in almost 60% of the dogs treated for mast cell tumors.
While some mast cell skin tumors are cancerous, most are benign, localized lumps in the skin. Still other mast cell tumors are cancerous, systemic tumors that can be found in the liver, gastrointestinal tract, spleen or bloodstream. However, systemic tumors were excluded from the study. Included only in the study were cancerous skin tumors.
Interestingly, localized, cancerous skin tumors can be removed surgically and have an excellent cure rate, unless they are very advanced tumors. Palladia is not a cure. It is a treatment (with a broad array of toxic side effects) and works only until the tumors begin to grow again.
Side effects include:
- Diarrhea: Almost half of the dogs had diarrhea (46%)
- Anorexia (39.1%)
- Lethargy (35.6%)
- Vomiting (32.2%)
- Lameness (17.2%)
- Weight loss (14,9%)
New studies are now being conducted with Palladia for canine osteosarcoma. One awaits the results with great interest.
Note: Vascustatin, a potent angiogenesis inhibitor with immune stimulating properties, is available online. No adverse side effects have been reported.
Filed under: Canine Osteosarcoma Mainstream Research
Like this post? Subscribe to my RSS feed and get loads more!